Home   News   Article

Covid-19 in Forres and Moray: NHS Grampian says Level 6 jabs will begin this week


By David Porter

Easier access to your trusted, local news. Subscribe to a digital package and support local news publishing.



Click here to sign up to our free newsletters!

Vaccinations will start again in Moray following a pause due to a lack of supplies.

North-east residents aged between 16 and 64 with one of the following conditions and are next in line for the Covid vaccine:

  • Chronic respiratory disease
  • Chronic heart disease and vascular disease
  • Chronic kidney disease
  • Chronic liver disease
  • Chronic neurological disease
  • Diabetes mellitus
  • Immunosuppression
  • Asplenia or dysfunction of the spleen
  • Morbid obesity
  • Severe mental illness

Also included is anyone eligible for a carer’s allowance and those who are the sole or primary carer of an elderly or disabled vulnerable person.

An NHS Grampian spokesperson said: "Our clinic activity has unfortunately been reduced recently due to a lower volume of national stock availability.

"However, we can assure the public our aim is to deliver at the maximum pace that stock allows.

"Tomorrow (Wednesday, February 24) our clinics will recommence with priority group 6.

"This group includes individuals with ‘at risk’ medical conditions and carers.

"Appointments will be sent in a phased way over the next two weeks."

Nearly 145,000 people in Moray, Aberdeenshire and Aberdeen have received their first dose of Covid-19 vaccine to date.

This includes the majority of people aged over 65 years.

Those who haven't been given a vaccination appointment yet can either complete the form available here or call 0800 030 8013.

Work is also under way to identify people who could be classed as carers but are not included in official records.

It's possible to self-register here



Do you want to respond to this article? If so, click here to submit your thoughts and they may be published in print.



This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More